Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E
Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Minim Invasive Neurosurg. 2007 Oct;50(5):273-80. doi: 10.1055/s-2007-991143.
The objective of this study was to investigate the histological correlate of (11)C-methionine (MET) PET uptake of brain gliomas by image fusion for navigated surgery.
Twenty-seven patients (18 male, 9 female; mean age 42 years; range 11-77 years; 8 low-grade and 11 high-grade astrocytomas or mixed gliomas, 8 oligodendrogliomas) underwent MET PET studies preoperatively.
MET PET tumor uptake was detected in 26 of 27 patients (96.3%). The quantitative MET tumor standardized uptake value (SUV) ratio was significantly higher in malignant gliomas and oligodendrogliomas than in low-grade gliomas (2.76/2.62 vs. 1.67, p=0.03). Generally, qualitative visual grading of MET uptake revealed 2 main patterns: focal MET uptake in 12 and uniform global MET uptake in 11 patients. Focal uptake corresponded to malignant glioma histology in 66.7%, and uniform global uptake to oligodendroglial histology in 72.7%. In oligodendrogliomas, global MET uptake constituted 81.5% (range 53.8-135%) of the MRI T(1) tumor volume on average and was limited to the MRI FLAIR tumor volume in 86% (7/8) of patients. Tissue samples of focal MET uptake areas correlated with histological anaplasia in 66.6% (8/12 glioma patients), although 62.5% (5/8 patients) lacked MRI contrast enhancement.
MET PET image fusion may facilitate the targeting of anaplastic foci in homogeneous MRI non-enhancing gliomas for biopsy, may identify oligodendroglial histology preoperatively as well as characterize biologically active tumor volumes within MRI T(1)/FLAIR tumor areas of candidate patients for resection.
本研究的目的是通过图像融合研究脑胶质瘤(11)C-蛋氨酸(MET)PET摄取的组织学相关性,以用于导航手术。
27例患者(18例男性,9例女性;平均年龄42岁;年龄范围11 - 77岁;8例低级别和11例高级别星形细胞瘤或混合性胶质瘤,8例少突胶质细胞瘤)术前行MET PET研究。
27例患者中有26例(96.3%)检测到MET PET肿瘤摄取。恶性胶质瘤和少突胶质细胞瘤的定量MET肿瘤标准化摄取值(SUV)比率显著高于低级别胶质瘤(2.76/2.62对1.67,p = 0.03)。一般来说,MET摄取的定性视觉分级显示2种主要模式:12例患者为局灶性MET摄取,11例患者为均匀性整体MET摄取。局灶性摄取在66.7%的情况下对应恶性胶质瘤组织学,均匀性整体摄取在72.7%的情况下对应少突胶质细胞组织学。在少突胶质细胞瘤中,整体MET摄取平均占MRI T(1)肿瘤体积的81.5%(范围53.8 - 135%),86%(7/8)的患者局限于MRI FLAIR肿瘤体积。局灶性MET摄取区域的组织样本在66.6%(8/12例胶质瘤患者)中与组织学间变相关,尽管62.5%(5/8例患者)缺乏MRI对比增强。
MET PET图像融合可能有助于在MRI无强化的均匀性胶质瘤中靶向间变性病灶进行活检,术前可识别少突胶质细胞组织学,并在候选切除患者的MRI T(1)/FLAIR肿瘤区域内表征生物活性肿瘤体积。